Search

Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics
Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Named One of The Boston Globe’s Top Places to Work 2020
Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
Recruiting Fraud